SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

Inclusion Criteria: * Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage; * Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the HBM guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening; * Age ≥ 18 years; * At least three months life-expectancy; * Written informed consent according to ICH/GCP and national/local regulations. Exclusion Criteria: * Any active malignancy, except pT1-2 prostatic cancer Gleason score \< 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry; * Active hepatitis B/C or HIV; * Any secondary malignancy; * Any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.